ArticleViruses2026
Synthesis and Broad-Spectrum Antiviral Evaluation of Novel 1,2,3-Triazole-Quinoline Derivatives Targeting SARS-CoV-2, Influenza, DENV-2, and CHIKV.
Alcione Silva de Carvalho, Natalia Fintelman-Rodrigues, Victória Toledo Diniz de Camargo, Lina Silva-Trujillo, Caroline Souza de Freitas, Isabela Alencar Graciano, Acácio Silva de Souza, Camilla Blanco de Assis, Otávio Augusto Chaves, Fernando de Carvalho da Silva and 2 more
Abstract read
In one paragraphArticle in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Alcione Silva de CarvalhoPrograma de Pós-Graduação em Ciências Aplicadas a Produtos para a Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói 24241-000, RJ, Brazil.
Natalia Fintelman-RodriguesLaboratory of Immunopharmacology, Center for Research, Innovation, and Surveillance in COVID-19 and Health Emergencies, Oswaldo Cruz Institute, Rio de Janeiro 21040-361, RJ, Brazil.ORCID 0000-0002-2332-8338 Victória Toledo Diniz de CamargoPrograma de Pós-Graduação em Ciências Aplicadas a Produtos para a Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói 24241-000, RJ, Brazil.
Lina Silva-TrujilloLaboratory of Immunopharmacology, Center for Research, Innovation, and Surveillance in COVID-19 and Health Emergencies, Oswaldo Cruz Institute, Rio de Janeiro 21040-361, RJ, Brazil.ORCID 0000-0001-5503-5057 Caroline Souza de FreitasLaboratory of Immunopharmacology, Center for Research, Innovation, and Surveillance in COVID-19 and Health Emergencies, Oswaldo Cruz Institute, Rio de Janeiro 21040-361, RJ, Brazil.ORCID 0000-0001-8100-0472 Isabela Alencar GracianoPrograma de Pós-Graduação em Ciências Aplicadas a Produtos para a Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói 24241-000, RJ, Brazil.
Acácio Silva de SouzaPrograma de Pós-Graduação em Ciências Aplicadas a Produtos para a Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói 24241-000, RJ, Brazil.
Camilla Blanco de AssisLaboratory of Immunopharmacology, Center for Research, Innovation, and Surveillance in COVID-19 and Health Emergencies, Oswaldo Cruz Institute, Rio de Janeiro 21040-361, RJ, Brazil.ORCID 0000-0003-0097-9864 Otávio Augusto ChavesLaboratory of Immunopharmacology, Center for Research, Innovation, and Surveillance in COVID-19 and Health Emergencies, Oswaldo Cruz Institute, Rio de Janeiro 21040-361, RJ, Brazil.ORCID 0000-0001-6211-7659 Fernando de Carvalho da SilvaDepartamento de Química Orgânica, Instituto de Química, Universidade Federal Fluminense, Niterói 24020-141, RJ, Brazil.ORCID 0000-0002-2042-3778 Vitor F FerreiraPrograma de Pós-Graduação em Ciências Aplicadas a Produtos para a Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói 24241-000, RJ, Brazil.ORCID 0000-0002-2166-766X Thiago Moreno L SouzaLaboratory of Immunopharmacology, Center for Research, Innovation, and Surveillance in COVID-19 and Health Emergencies, Oswaldo Cruz Institute, Rio de Janeiro 21040-361, RJ, Brazil.
Funding
Brazilian Federal Agency for Support and Evaluation of Graduate Education 465313/2014-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 304243/2024-8Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/203.954/2024
6 · The paper itselfAbstract
The persistent global threat posed by emerging and re-emerging RNA viruses, including SARS-CoV-2, influenza A(H1N1)pdm09, DENV-2, and CHIKV, highlights the critical need for novel and broad-spectrum antiviral agents. Building upon the established antiviral activity of the quinoline scaffold, this study employed a molecular hybridization strategy to design and synthesize a novel series of 1,2,3-triazole-quinoline derivatives (compounds
Indexed as
Antiviral AgentsChikungunya virusDengue VirusQuinolinesSARS-CoV-2TriazolesAnimalsCell LineHumansInfluenza A Virus, H1N1 SubtypeMolecular Docking SimulationAntiviral AgentsQuinolinesTriazolesantiviral discoverybroad-spectrum antiviral agentsmolecular hybridization
Identifiers
PMID42797784
PMCPMC13611932
What OpenQuestion holds
Textmetadata
Read underepoch 390